Ruti Aga: Six Years, One Forged Prescription, and a Knee Injection That Was Legal

A single sheet of paper. A doctor's name, a clinic address, and one line prescribing a knee injection. The Athletics Integrity Unit's statement on Thursday left all three ends of that sheet exposed. The clinic named on it said no doctor by that name had ever been registered there. The person who wrote it was a family member of Ruti Aga, with no medical registration at all. Asked to explain, that person said he had used "an old prescription pad from a former workplace." The clinic disowned that claim too.

The price of that sheet: two years for the presence of a substance, four years for tampering. Six years in total, counted from 10 September — the same date her provisional suspension began.

I have spent three decades logging injuries and the excuses built around them. The first lesson here is plain: the six years were not written by the substance. They were written by the prescription.

Ruti Aga, Ethiopia, 32. An elite marathoner. She won the 2026 Tokyo Marathon and finished second at three World Marathon Majors. My own notes carry 2:18:34 from Berlin 2026, where she was second — that figure is not in the AIU statement, so treat it as pending verification. The statement gives no personal best, no splits, no field strength.

The recorded event is from March: a half marathon in China, which she won. Her time is not disclosed. A half marathon carries no Olympic qualifying function, so performance arithmetic is pointless here. One performance-relevant fact survives — she won — which tells us this was a World Athletics Label-tier elite field with in-competition testing. Without that tier, no AIU sample would exist.

The testing window for a road race opens at 23:59 the day before the race. An injection given four or five days earlier lands inside that window if residues persist. That technical detail is the hinge of the entire case, and it is the first thing to vanish from the headlines.

A correction is necessary, because the source text carries the error. Methylprednisolone is described there as a "prohibited steroid" classed as performance enhancing by WADA. Both halves are imprecise. Methylprednisolone is a glucocorticoid, class S9 on the WADA Prohibited List — not an anabolic steroid (class S1). And S9 substances are prohibited in-competition only, by injection, oral or rectal route.

The consequence is direct: a therapeutic knee injection given out of competition is entirely legal. It becomes a violation only if residues are present in an in-competition sample. This was never a "steroid" case. It was a route-and-timing case. The mislabelling makes the affair look dirtier than it is and buries the one legal argument that could have worked.

That is exactly where a defence existed. Intra-articular methylprednisolone for knee synovitis is standard practice in distance runners, from Haryana to the Ethiopian high-altitude camps. If the treatment was real and the records were real, the defence was straightforward: dates, route, medical necessity, a documented washout calculation. An athlete who has genuine paperwork does not commission a prescription.

The AIU statement records three independent verification failures. One, the clinic on the pad did not exist. Two, the author of the pad held no medical registration; he was family. Three, the "old prescription pad" explanation was rejected by the clinic itself. Three separate checks, three failures. That is not the signature of carelessness. It is the signature of intent.

And the pad was not produced spontaneously. It was produced in answer. The four-year tampering sanction attaches to statements made in interview as well as to documents. There is a dimension here that reporting usually skips: the language and translation conditions of AIU interviews with Ethiopian athletes. When your legal defence rests on an interview conducted outside your first language, every irregularity in your answers weighs double. That is not an excuse — it is a procedural fact, and it should be on the record.

Two years plus four years equals six. The combination is not arbitrary. For a specified substance where intent is not proven, the standard sanction is two years. For tampering, the standard sanction is four. Add them and you get six. The arithmetic tells us the panel rejected the no-significant-fault mitigation that would otherwise have reduced the presence sanction, potentially to a reprimand. It also tells us something subtler: forged documentation is itself circumstantial evidence of concealment intent, yet it was not used to inflate the presence sanction — it was charged separately. Two findings, not one; the process held its shape.

Backdating to 10 September is a procedural benefit, not a reduction. Time served under provisional suspension counts against the ban; in real terms the athlete gains nothing. And the arithmetic matters more than the date — the source does not state the year the ban ends, so trust the sum and not the calendar. Six years from 32 puts her return at 38, and Ethiopian women's marathon depth does not accommodate a 38-year-old returnee with a doping record.

Here the reporting is thinnest. The source never states the disqualification scope. Standard AIU practice is unambiguous: the result and prize money from the competition where the sample was collected are automatically annulled, and ranking points accrued after that date go with them. So the March half marathon in China — the win, the money, the points — is very probably gone. The article does not say so; the probability is high.

What survives is the record before March. The 2026 Tokyo title and the three Major second places do not fall automatically absent a finding of earlier use. That is the uncomfortable core of this case: an athlete keeps a genuine elite career and loses a future simultaneously.

The competitive landscape, meanwhile, barely moves — which is what makes it sociologically interesting. Ethiopian women's marathon depth is such that a 2:18–2:20 performer is not automatically selectable. Kenya's pool is comparably deep, with the difference sitting at the very top. Removing one athlete changes no national medal capacity by any measurable margin. What changes is the integrity landscape, and that is the actual subject.

A knee injury was cited in the defence. I find that claim technically credible and legally irrelevant. Chronic knee pathology is a well-documented load-bearing failure in marathoners: 150 to 180 kilometres a week, two to three times body weight per landing, the same valgus collapse repeated. Three landing frames before the fall, the knee line is already late. I learned that from running-gait frames, not from a single still, and the discipline of three frames is what keeps a decoder honest.

The real story, though, is not the knee. It is the structure around the knee. The prescription was issued under a clinic that did not exist, by a family member with no registration. That is not a filing error; it is the signature of an athlete operating without a credentialed team physician. Where a team doctor exists, there is an injection record, a TUE pathway, and a route-specific washout calculation. None of the three appears here.

My Russia 2026 log tracked 47 documented injury events across 64 matches, and it taught me a lesson that travels directly to road running: teams spend more energy concealing injuries than treating them. Marathons compress that incentive hardest, because a large share of income arrives as appearance fees — that is, as standing on the start line. When a knee hurts and a contract is at risk, the cheapest, most available tool is a glucocorticoid injection.

So the forged prescription is not simply one person's moral collapse. It is the output of a structure where medical support is informal, TUE infrastructure is absent, and injury is treated as a career risk to be hidden. The moral responsibility sits with whoever commissioned the document. The structural responsibility sits with those who run the structure and name no one.

I read the scan before the club read the room — a habit of mine, and the part of this case that stings most. The question is not what was taken. The question is what the athlete knew about her own body, who withheld it, and under what duty. Here the sequence runs backwards. Normally the club knows first and the athlete later; here the family produced the document and the athlete carried it to the AIU. Confidentiality and cover-up are separated by a thin line, and I wrote about that line when decoding Ross Barkley's transfer-window medical. Barkley's case had real records that were correctly kept private. This one had nothing worth protecting, because what was submitted was paper, not treatment.

The contrarian reading collides with the headlines. Media framed this as a steroid case. Pharmacology says methylprednisolone has no proven endurance performance benefit. It reduces inflammation and pain, which is precisely why it becomes a tool for masking injury rather than a tool for speed.

Which produces the strangest fact of the whole affair: six years for a substance that cannot make you faster. The sanction is not for the drug. It is for the document. And it signals that the enforcement frontier has shifted from detection to document verification. The next fight is not in the laboratory; it is in the prescription pad.

A second angle is less comfortable. China's label-race circuit is a lucrative, low-risk income tier for East African marathoners between Majors. It is also now the AIU's highest-yield testing ground. Two economies collide inside the same race — the appearance-fee economy and the testing economy — and that collision will generate more cases.

A third point is a matter of discipline for me. It is easy to turn this into AIU-versus-African-runners, or into a federation failure. Neither holds without a documented decision trail. The paper chain leads to one family member; whether an agent or management was investigated is not in the statement. I separate mechanism from management: the mechanism is visible — the absence of formal medical support — and I have no document that indicts management.

A fourth point is the trap for anyone writing from London. British Athletics and UK Sport high-performance medical assumptions do not transfer. Ethiopian road running runs on agent-club clusters and altitude camps, not a national medical service. Compare inputs — credentialed physios, TUE filings, interview language — not outputs.

Three things to watch. The CAS appeal window, typically about 21 days from the reasoned decision; a document-based forgery finding is hard to overturn. The disqualification scope, and whether the AIU publicly confirms the March result and prize money as annulled. And whether any agent, manager or camp-level medical adviser is named at all.

And a fourth, which matters most. Cases in this family — a substance violation first, a heavy document violation second — are not isolated. They are fed by the same informal medical networks, and those networks serve dozens of athletes. Until a public document-verification protocol exists, the next case is already in the pipeline.

The career is over. That is the easiest sentence to write and the least useful. The harder question is whether the next marathoner standing on a start line with a sore knee will have real paper to show, or just an old prescription pad.